An open-label study of tiagabine as augmentation therapy for anxiety.

Background: At least 50% of patients with anxiety disorders experience only partial response to pharmacotherapy and require augmentation therapy. Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the CNS, and agents that modulate GABA neurotransmission have shown promise in the treatment of anxiety disorders and are often used as augmentation agents.

Objective: This study evaluated tiagabine, a selective GABA reuptake inhibitor (SGRI), as augmentation therapy.